Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials

References

• KesslerRCBerglundPDemlerOThe epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)JAMA2003289233095310512813115
   PubMed Web of Science ®Google Scholar
• KulkarniSKDhirACurrent investigational drugs for major depressionExpert Opin Investig Drugs2009186767788
   PubMed Web of Science ®Google Scholar
• AshtonAKJamersonBDWeinsteinLWWagonerCAntidepressant-related adverse effects impacting treatment compliance: results of a patient surveyCurr Ther Res Clin Exp20056629610624672116
   PubMed Web of Science ®Google Scholar
• GeddesJRCarneySMDaviesCRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic reviewLancet2003361935865366112606176
   PubMed Web of Science ®Google Scholar
• FavaMRushAJAlpertJEDifference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D reportAm J Psychiatry2008165334235118172020
   PubMed Web of Science ®Google Scholar
• DawsonLAWatsonJMVilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disordersCNS Neurosci Ther200915210711719499624
   PubMed Web of Science ®Google Scholar
• CoplanJDGopinathSAbdallahCGBerryBRA neurobiological hypothesis of treatment-resistant depression – mechanisms for selective serotonin reuptake inhibitor non-efficacyFront Behav Neurosci2014818924904340
   PubMed Web of Science ®Google Scholar
• PortellaMJde Diego-AdelinoJBallesterosJCan we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depressionJ Clin Psychiatry201172796296921034693
   PubMed Web of Science ®Google Scholar
• KehneJHBartoszykGDGreinerHEIn vitro characterization of vilazodone as a dual-acting serotonin reuptake receptor and 5-HT1A receptor partial agonistPoster presented at: 65th Annual Meeting of the Society of Biological Psychiatry Meeting2010
   Google Scholar
• RickelsKAthanasiouMReedCVilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depressionPersonali Med20096216224
   Web of Science ®Google Scholar
• ThaseMEChenDEdwardsJRuthAEfficacy of vilazodone on anxiety symptoms in patients with major depressive disorderInt Clin Psychopharmacol201429635135624978955
   PubMed Web of Science ®Google Scholar
• RickelsKAthanasiouMRobinsonDSGibertiniMWhalenHReedCREvidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry200970332633319284933
   PubMed Web of Science ®Google Scholar
• KhanACutlerAJKajdaszDKA randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorderJ Clin Psychiatry201172444144721527122
   PubMed Web of Science ®Google Scholar
• CroftHAPomaraNGommollCChenDNunezRMathewsMEfficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry20147511e1291e129825470094
   PubMed Web of Science ®Google Scholar
• MathewsMGommollCChenDNunezRKhanAEfficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trialInt Clin Psychopharmacol2015302677425500685
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationBMJ2009339b270019622552
   PubMed Web of Science ®Google Scholar
• ShiLPuJXuLMalaguitJZhangJChenSThe efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population – an updated meta-analysisBMC Neurol201414125125527141
   PubMedGoogle Scholar
• KennedySHAndersenHFLamRWEfficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysisJ Psychiatry Neurosci200631212213116575428
   PubMed Web of Science ®Google Scholar
• SzegediAJansenWTvan WilligenburgAPvan der MeulenEStassenHHThaseMEEarly improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patientsJ Clin Psychiatry200970334435319254516
   PubMed Web of Science ®Google Scholar
• StorosumJGElferinkAJvan ZwietenBJvan den BrinkWHuyserJNatural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studiesPharmacopsychiatry2004371323614750046
   PubMed Web of Science ®Google Scholar
• PapakostasGIPerlisRHScaliaMJPetersenTJFavaMA meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorderJ Clin Psychopharmacol2006261566016415707
   PubMed Web of Science ®Google Scholar
• RaoSZisookSAnxious depression: clinical features and treatmentCurr Psychiatry Rep200911642943619909663
   PubMed Web of Science ®Google Scholar
• ClaytonPJGroveWMCoryellWKellerMHirschfeldRFawcettJFollow-up and family study of anxious depressionAm J Psychiatry199114811151215171928465
   PubMed Web of Science ®Google Scholar
• FlintAJRifatSLTwo-year outcome of elderly patients with anxious depressionPsychiatry Res199766123319061801
   PubMed Web of Science ®Google Scholar
• RobinsonDSKajdaszDKGallipoliSWhalenHWamilAReedCRA 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorderJ Clin Psychopharmacol201131564364621869687
   PubMed Web of Science ®Google Scholar
• WardenDRushAJTrivediMHFavaMWisniewskiSRThe STAR*D Project results: a comprehensive review of findingsCurr Psychiatry Rep20079644945918221624
   PubMedGoogle Scholar
• MachadoMIskedjianMRuizIEinarsonTRRemission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trialsCurr Med Res Opin20062291825183716968586
   PubMed Web of Science ®Google Scholar
• Montejo-GonzalezALLlorcaGIzquierdoJASSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patientsJ Sex Marital Ther19972331761949292833
   PubMed Web of Science ®Google Scholar
• AlcantaraAGA possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctionsJ Sex Marital Ther199925212512910327381
   PubMed Web of Science ®Google Scholar